Listen on the go
CORRECT!
Next question
touchRESPIRATORY touchRESPIRATORY
Allergy, COVID-19
Watch Time: 5 mins

Ronald Strauss, AAAAI 2022: the Impact of Eosinophilia on COVID-19 Outcomes

Share this Video
Copy Link
Published Online: Apr 5th 2022

touchRESPIRATORY were delighted to talk with Dr Ronald Strauss (Cleveland Allergy and Asthma Center; Case Western Reserve University Medical School, Cleveland, OH, USA) around his analysis of the association of eosinophilia with improved COVID-19 outcomes in patients treated with inhaled corticosteroids.

The abstract ‘Eosinophilia is Associated with Improved COVID-19 Outcomes in Patients Treated with Inhaled Corticosteroids.’ was presented at AAAAI 2022, 25-28 February.

Questions

  1. What is known about the relationship between eosinophilia and COVID-19 outcomes? (0:19)
  2. What was the rationale for the analysis you are presenting? (0:56)
  3. What were the findings of this analysis? (1:44)
  4. What questions remain unanswered and what future studies are planned? (3:38)

Disclosures: Ronald Strauss has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the AAAAI meeting 2022.

Related Videos In COVID-19
COVID-19
Developed by Touch
Findings from the COVA study of BIO101 in severe COVID-19: Girish B. Nair, ATS 2023
Watch Time: 6 mins

The COVA study (NCT04472728) was a double-blind, placebo-controlled phase 2 to 3 study that investigated BIO101 for the prevention of respiratory deterioration in hospitalized COVID-19. touchRESPIRATORY were delighted to speak with Dr. Girish B. Nair (Beaumont Health, Royal Oak, MI, USA) around the mechanism of action of BIO101, the design, inclusion criteria and findings from […]

COVID-19
Developed by Touch
Margaret Pisani, Research highlights in COVID-19 from 2022
Watch Time: 2 mins

Longitudinal studies into the long-term impact of COVID-19 are currently at the forefront of research, touchRESPIRATORY interviewed editorial board member Prof. Margaret Pisani (Yale School of Medicine. New Haven, CT, USA) about what to look out for in 2023 in this area. Disclosures: Margaret Pisani has nothing to disclose in relation to this video interview. Support: Interview and filming […]

COVID-19
Developed by Touch
Alan Kaplan: IPCRG COVID-19 and Respiratory Q&A – COVID-19 Controversies, Vaccination and Booster Doses
Watch Time: 8 mins

The IPCRG COVID-19 and Respiratory Q&A is providing evidence based COVID and respiratory advice to practising primary care clinicians. Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) answers questions from the Q&A on managing COVID-19, how to address the controversies surrounding the COVID-19 vaccines, and the immunity provided from COVID-19 vaccination and booster doses. […]

Trending In COVID-19:

Findings from the COVA study of BIO101 in severe COVID-19: Girish B. Nair, ATS 2023
COVID-19
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72